CA2703792A1 - Corticosteroids to treat epothilone or epothilone derivative induced diarrhea - Google Patents
Corticosteroids to treat epothilone or epothilone derivative induced diarrhea Download PDFInfo
- Publication number
- CA2703792A1 CA2703792A1 CA2703792A CA2703792A CA2703792A1 CA 2703792 A1 CA2703792 A1 CA 2703792A1 CA 2703792 A CA2703792 A CA 2703792A CA 2703792 A CA2703792 A CA 2703792A CA 2703792 A1 CA2703792 A1 CA 2703792A1
- Authority
- CA
- Canada
- Prior art keywords
- epothilone
- antidiarrheal agent
- epothilone derivative
- treatment
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003883 epothilone derivatives Chemical class 0.000 title claims abstract description 68
- 239000003246 corticosteroid Substances 0.000 title claims abstract description 25
- 206010012735 Diarrhoea Diseases 0.000 title claims description 53
- 229930013356 epothilone Natural products 0.000 title claims description 7
- 229960001334 corticosteroids Drugs 0.000 title description 6
- 229940125714 antidiarrheal agent Drugs 0.000 claims abstract description 46
- 239000003793 antidiarrheal agent Substances 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 230000002062 proliferating effect Effects 0.000 claims abstract description 13
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical group C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 64
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 33
- 229960005205 prednisolone Drugs 0.000 claims description 33
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229960004618 prednisone Drugs 0.000 claims description 14
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940126062 Compound A Drugs 0.000 claims description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 4
- 229950007460 patupilone Drugs 0.000 description 50
- 206010028980 Neoplasm Diseases 0.000 description 36
- 241000700159 Rattus Species 0.000 description 26
- 230000037396 body weight Effects 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- -1 e.g. Chemical group 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 108010046780 hydrocortisone receptor Proteins 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 201000002025 prostate sarcoma Diseases 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98663507P | 2007-11-09 | 2007-11-09 | |
| US60/986,635 | 2007-11-09 | ||
| PCT/US2008/079936 WO2009061587A1 (en) | 2007-11-09 | 2008-10-15 | Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2703792A1 true CA2703792A1 (en) | 2009-05-14 |
Family
ID=40087318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2703792A Abandoned CA2703792A1 (en) | 2007-11-09 | 2008-10-15 | Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100267682A1 (enExample) |
| EP (1) | EP2222286A1 (enExample) |
| JP (1) | JP2011503075A (enExample) |
| KR (1) | KR20100096077A (enExample) |
| CN (1) | CN101848708B (enExample) |
| AU (1) | AU2008325016A1 (enExample) |
| BR (1) | BRPI0820338A2 (enExample) |
| CA (1) | CA2703792A1 (enExample) |
| MX (1) | MX2010005119A (enExample) |
| RU (1) | RU2010123028A (enExample) |
| WO (1) | WO2009061587A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| CA3105575A1 (en) * | 2013-01-15 | 2014-07-24 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator and uses thereof |
| EP3519592B1 (en) * | 2016-09-27 | 2022-03-09 | Mayo Foundation for Medical Education and Research | Materials and methods for evaluating cancer |
| UA129105C2 (uk) | 2017-10-16 | 2025-01-15 | Арагон Фармасьютикалз, Інк. | Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози |
| US10705435B2 (en) | 2018-01-12 | 2020-07-07 | Globalfoundries Inc. | Self-referencing and self-calibrating interference pattern overlay measurement |
| US11686576B2 (en) | 2020-06-04 | 2023-06-27 | Kla Corporation | Metrology target for one-dimensional measurement of periodic misregistration |
| US11796925B2 (en) | 2022-01-03 | 2023-10-24 | Kla Corporation | Scanning overlay metrology using overlay targets having multiple spatial frequencies |
| US12032300B2 (en) | 2022-02-14 | 2024-07-09 | Kla Corporation | Imaging overlay with mutually coherent oblique illumination |
| US12487190B2 (en) | 2022-03-30 | 2025-12-02 | Kla Corporation | System and method for isolation of specific fourier pupil frequency in overlay metrology |
| US12422363B2 (en) | 2022-03-30 | 2025-09-23 | Kla Corporation | Scanning scatterometry overlay metrology |
| US12235588B2 (en) | 2023-02-16 | 2025-02-25 | Kla Corporation | Scanning overlay metrology with high signal to noise ratio |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231894A (zh) * | 1998-04-14 | 1999-10-20 | 陈水清 | 止泻栓 |
| PT1372650E (pt) * | 2001-03-19 | 2009-02-25 | Novartis Ag | Associações compreendendo um agente antidiarreico e uma epotilona ou um derivado de epotilona |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| EP1553939A1 (en) * | 2002-10-11 | 2005-07-20 | Dana-Farber Cancer Institute, Inc. | Epothilone derivatives for the treatment of multiple myeloma |
| MX2007000971A (es) * | 2004-07-26 | 2007-04-10 | Novartis Ag | Combinaciones de epotilina. |
-
2008
- 2008-10-15 US US12/741,680 patent/US20100267682A1/en not_active Abandoned
- 2008-10-15 MX MX2010005119A patent/MX2010005119A/es not_active Application Discontinuation
- 2008-10-15 RU RU2010123028/15A patent/RU2010123028A/ru not_active Application Discontinuation
- 2008-10-15 CN CN2008801149548A patent/CN101848708B/zh not_active Expired - Fee Related
- 2008-10-15 WO PCT/US2008/079936 patent/WO2009061587A1/en not_active Ceased
- 2008-10-15 CA CA2703792A patent/CA2703792A1/en not_active Abandoned
- 2008-10-15 AU AU2008325016A patent/AU2008325016A1/en not_active Abandoned
- 2008-10-15 EP EP08848076A patent/EP2222286A1/en not_active Withdrawn
- 2008-10-15 JP JP2010533139A patent/JP2011503075A/ja active Pending
- 2008-10-15 BR BRPI0820338A patent/BRPI0820338A2/pt not_active IP Right Cessation
- 2008-10-15 KR KR1020107010102A patent/KR20100096077A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008325016A1 (en) | 2009-05-14 |
| EP2222286A1 (en) | 2010-09-01 |
| WO2009061587A1 (en) | 2009-05-14 |
| CN101848708B (zh) | 2013-01-02 |
| US20100267682A1 (en) | 2010-10-21 |
| CN101848708A (zh) | 2010-09-29 |
| MX2010005119A (es) | 2010-05-27 |
| BRPI0820338A2 (pt) | 2017-05-02 |
| KR20100096077A (ko) | 2010-09-01 |
| JP2011503075A (ja) | 2011-01-27 |
| RU2010123028A (ru) | 2011-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2703792A1 (en) | Corticosteroids to treat epothilone or epothilone derivative induced diarrhea | |
| US20110033458A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| AU2009267016B2 (en) | Use of mifepristone for the treatment of Amyotrophic Lateral Sclerosis | |
| JP2010531333A (ja) | ヒトを除く哺乳類動物の心不全の治療用組成物および治療方法 | |
| CN104349771A (zh) | 用于治疗肿瘤疾病的17α-羟化酶(C17,20-裂解酶)抑制剂和特定PI-3K抑制剂的组合 | |
| Sutanto et al. | Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects | |
| WO2008003363A1 (de) | Pharmazeutische zubereitung zur kontrazeption und zur verminderung des risikos angeborener fehlbildungen | |
| DE60108710T2 (de) | Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel | |
| US20040067918A1 (en) | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative | |
| US6274621B1 (en) | Ginkgolides for inhibition of membrane expression of benzodiazepine receptors | |
| WO2005079792A1 (ja) | 重症糖尿病網膜症の予防又は治療剤 | |
| US20030219401A1 (en) | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent | |
| DE60316775T2 (de) | Kombinationspräparat aus epothilone derivate und imidazotetrazinone | |
| EP0862428B1 (en) | Ginkgolides for inhibition of membrane expression | |
| KR20250102046A (ko) | 다주코릴란트를 이용한 근위축성 측삭경화증의 치료 | |
| US20140378426A1 (en) | Methods and compositions for enhancing visual function | |
| JPH08508502A (ja) | 骨粗しょう症の治療方法および治療用組成物 | |
| KR20250144469A (ko) | 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물 | |
| AU2008200068B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| US7625916B2 (en) | Medicinal composition | |
| KR20040107482A (ko) | 알도스테론 수용체 길항물질 및 피브르산 유도체의 혼합물 | |
| Wesseling et al. | Abstracts of papers | |
| HK1072723B (en) | Combinations comprising an epothilone derivatives and an imidazotetrazinone | |
| NZ537040A (en) | Treating a proliferative disease comprising administering to the animal a combination that comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent | |
| HK1141234A (en) | Combinations comprising epothilones and pharmaceutical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20141015 |